Holen Sie sich die Stockscreener-App
11.60
3.66%
0.41
Vorhandelsmarkt:
11.48
-0.12
-1.03%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$11.19
Offen:
$11.2
24-Stunden-Volumen:
9.32M
Relative Volume:
1.01
Marktkapitalisierung:
$13.36B
Einnahmen:
$14.33B
Nettoeinkommen (Verlust:
$-3.79B
KGV:
-3.6593
EPS:
-3.17
Netto-Cashflow:
$1.84B
1W Leistung:
+7.01%
1M Leistung:
+14.06%
6M Leistung:
+28.32%
1J Leistung:
-7.27%
1-Tages-Spanne:
$11.10
$11.63
1-Wochen-Bereich:
$10.67
$11.63
52-Wochen-Spanne:
$6.85
$13.13
Viatris Inc Stock (VTRS) Company Profile
Firmenname
Viatris Inc
Sektor
Telefon
(724) 514-1465
Adresse
1000 MYLAN BOULEVARD, CANONSBURG
Vergleichen Sie VTRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
11.60 | 12.89B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
118.07 | 51.01B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.37 | 45.05B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.46 | 41.46B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.80 | 32.77B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
484.86 | 20.51B | 3.08B | 1.24B | 1.07B | 25.61 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-06-06 | Eingeleitet | Goldman | Neutral |
| 2024-07-19 | Fortgesetzt | Jefferies | Buy |
| 2023-10-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-10 | Hochstufung | UBS | Sell → Neutral |
| 2022-11-08 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Fortgesetzt | Jefferies | Hold |
| 2022-06-14 | Eingeleitet | UBS | Sell |
| 2022-05-10 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Eingeleitet | Citigroup | Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Eingeleitet | Argus | Hold |
| 2020-12-14 | Eingeleitet | Bernstein | Mkt Perform |
Alle ansehen
Viatris Inc Aktie (VTRS) Neueste Nachrichten
Viatris to Sell Entire Equity Stake in Biocon Biologics for $815 Million - Voice Of HealthCare
Barclays Initiates Coverage of Viatris (VTRS) with Overweight Recommendation - Nasdaq
Barclays Initiates Viatris at Overweight With $15 Price Target - marketscreener.com
Viatris to sell equity stake in Biocon Biologics to Biocon for $815M - MSN
Generic Drugs Market to Reach US$ 942.69 Billion by 2033 at 7.1% - openPR.com
CAM, Khaitan act on Biocon Limited acquiring stake in Biocon Biologics from Serum, Viatris - Bar and Bench
Viatris Inc. Stock Rises Friday, Outperforms Market - 富途牛牛
Viatris Sells Biocon Biologics Stake for $815 Million - TipRanks
Viatris Inc Announces Agreement to Monetize Biocon Biologics Stake - TradingView
Viatris to Sell its Equity Stake in Biocon Biologics for $815 Million - marketscreener.com
Viatris signs agreements with Biocon on $815m stake sale - Yahoo Finance
Viatris sells Biocon Biologics stake for $815 million in cash and equity deal (VTRS:NASDAQ) - Seeking Alpha
Viatris sells Biocon Biologics stake for $815 million - MSN
Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln - Nasdaq
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited - PR Newswire
Biocon To Absorb Biocon Biologics, Pursue Rs 4,500 Cr QIP To Fund Viatris Payout - BW Businessworld
Biocon to absorb biologics unit, eyes Rs 4,500 cr fund raise to buy Viatris’s residual stake - Moneycontrol
Biocon integrates Biocon Biologics; to raise ₹4,500 crore via QIP to fund Viatris payout - BusinessLine
Viatris shareholders elect directors and approve proposals at annual meeting By Investing.com - Investing.com Nigeria
Viatris Holds Annual Shareholder Meeting on December 5 - TipRanks
Viatris shareholders elect directors and approve proposals at annual meeting - Investing.com India
Mark Cuban Takes Aim at FDA Fees - GuruFocus
Why Viatris Inc. (VIA) stock trades below fair valueJuly 2025 Pullbacks & Weekly Top Gainers Alerts - Newser
Mark Cuban calls for end to generic drug application fees to boost domestic manufacturing - Seeking Alpha
Can Viatris Inc. (VIA) stock survive global slowdownWall Street Watch & Free Daily Entry Point Trade Alerts - Newser
Can Viatris Inc. (VIA) stock surprise markets with earningsTrade Volume Summary & Low Drawdown Momentum Ideas - Newser
What is the fair value estimate for Viatris Inc. (VIA) stock in 2025Weekly Stock Analysis & AI Based Buy/Sell Signal Reports - Newser
Why Viatris Inc. (VIA) stock is a must watch tickerJuly 2025 Patterns & Risk Controlled Daily Plans - Newser
Is Viatris Inc. (VIA) stock a good hedge against inflationMarket Growth Summary & Stock Portfolio Risk Management - Newser
How Viatris Inc. stock benefits from global expansion2025 Top Gainers & High Conviction Investment Ideas - Newser
Will Viatris Inc. (VIA) stock extend growth storyMarket Risk Summary & Risk Managed Investment Strategies - Newser
How Viatris Inc. (VIA) stock compares with market leadersWeekly Stock Report & Step-by-Step Swing Trade Plans - Newser
Viatris Inc.: Revenue and Earnings Analysts Forecasts Revisions | VTRS | US92556V1061 - marketscreener.com
Viatris Inc.: Target Price Consensus and Analysts Recommendations | VTRS | US92556V1061 - marketscreener.com
Viatris Inc.: Financial Data Forecasts Estimates and Expectations | VTRS | US92556V1061 - marketscreener.com
Viatris Inc.: Dividend historical data and projections - marketscreener.com
What market sentiment indicators show for Viatris Inc. (VIA) stockJuly 2025 Big Picture & Technical Buy Zone Confirmations - Newser
Behavioral Patterns of VTRS and Institutional Flows - news.stocktradersdaily.com
Levi & Korsinsky Notifies Viatris Inc. (VTRS) Shareholders of Class Action Lawsuit and June 3, 2025 Deadline - The National Law Review
VTRS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
How Viatris Inc. (VIA) stock trades after earningsMarket Rally & Risk Controlled Stock Pick Alerts - moha.gov.vn
Non-operating income (total) of Viatris, Inc. – SIX:VTRS - TradingView
Viatris Inc. (VIA.DE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Shareholders That Lost Money on Viatris Inc. (VTRS) Should Contac - The National Law Review
These 10 S&P 500 Stocks Are Dirt Cheap This Black Friday - Benzinga
Merz Loses Bid To Block Viatris In Unified Patent Court - Law360
What Do Recent Portfolio Streamlining Moves Mean for Viatris’s True Value in 2025? - Yahoo Finance
Merz fails with PI request in first ever SPC case against Viatris - JUVE Patent
Fondaparinux Market Set to Significantly Grow from 2025 to 2032 | - openPR.com
Viatris to Participate in Upcoming Investor Conferences - Finviz
Pfizer, UnitedHealth, Viatris, Addus HomeCare, and Quest Stocks Trade Up, What You Need To Know - The Globe and Mail
Finanzdaten der Viatris Inc-Aktie (VTRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.29%
4.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):